PT-141 (Bremelanotide): Libido Evidence, Not Hype
An FDA-approved melanocortin-receptor peptide for low sexual desire in premenopausal women. Here is what the pivotal phase 3 trials actually measured — and where the viral “metabolic longevity” claims run ahead of the science.
How It Works
Unlike PDE5 inhibitors (Viagra), which act on genital blood flow, bremelanotide activates melanocortin receptors — chiefly MC4R — in the hypothalamus, central-nervous-system pathways tied to sexual desire and arousal.
It is self-injected as a 1.75 mg dose under the skin roughly 45 minutes before anticipated activity, as needed — not taken on a daily schedule like most prescription drugs.
MC4R signaling also governs energy balance, which is why other melanocortin agonists such as setmelanotide are studied for obesity. That is a different molecule — not evidence that bremelanotide itself affects weight.
What the Data Shows
Key Takeaways
- FDA-approved as Vyleesi in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
- In two phase 3 RECONNECT trials (1,267 women), bremelanotide produced statistically significant improvements in sexual desire and reductions in related distress versus placebo (integrated FSFI-desire +0.35, P<.001).
- It works centrally through melanocortin (MC4R) receptors in the brain — a different mechanism than PDE5 inhibitors, and it is not associated with the blood-pressure drop seen with those drugs.
- Dosing is on-demand: 1.75 mg subcutaneously, as needed, not daily.
- Nausea is the most common side effect (about 40% with long-term use); flushing and headache are also common.
- The measured benefit is modest: independent reviewers describe the overall clinical benefit as “modest,” and female-desire trials carry a large placebo effect.
- There is no peer-reviewed evidence that bremelanotide improves weight, metabolic health, or longevity. Viral “metabolic dual-use” claims extrapolate from a different MC4R drug (setmelanotide) and unpublished announcements.
- It is studied and approved only in premenopausal women; efficacy and safety for men, postmenopausal women, or general “libido enhancement” are not established by the pivotal trials.
- It can transiently raise blood pressure and is not recommended with uncontrolled hypertension or known cardiovascular disease.
- Long-term data beyond about 76 weeks of use are limited.
Frequently Asked Questions
What is PT-141 (bremelanotide)?
PT-141, or bremelanotide, is a synthetic melanocortin-receptor peptide. It was FDA-approved as Vyleesi in 2019 to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, given as an on-demand 1.75 mg subcutaneous injection.
How does PT-141 work?
It activates melanocortin receptors (mainly MC4R) in the hypothalamus, influencing central brain pathways involved in sexual desire and arousal. This differs from Viagra-type PDE5 inhibitors, which act peripherally on genital blood flow rather than in the brain.
Does PT-141 help with weight loss or metabolism?
No published trial shows that bremelanotide improves weight or metabolic health. The melanocortin (MC4R) system does regulate appetite, and a different MC4R agonist — setmelanotide — is used for certain genetic forms of obesity, but that evidence does not transfer to bremelanotide. Treat “metabolic longevity” claims about PT-141 as unproven.
What are the side effects of PT-141?
The most common side effect is nausea, reported by about 40% of users with long-term use, followed by flushing and headache. It can transiently raise blood pressure, so it is not recommended for people with uncontrolled hypertension or cardiovascular disease.
Is PT-141 effective?
In the phase 3 RECONNECT trials it produced statistically significant but modest improvements in sexual desire and related distress compared with placebo. Reviewers caution that trials of female desire have a large placebo effect, so the real-world benefit for any individual can be small.
🧪 Buy PT-141 (Bremelanotide) 10mg — Research Grade
Swiss Chems publishes third-party HPLC COAs for selected products — vendor-published, a claim to verify. Deep-linked to the PT-141 (Bremelanotide) 10mg product page.
Buy PT-141 (Bremelanotide) 10mg at Swiss Chems →Affiliate links — support HighPeptides at no extra cost.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
PT-141 (bremelanotide/Vyleesi) is a prescription medication in the United States; use it only under the supervision of a licensed clinician.
We may earn a commission from qualifying purchases made through links on this page.